Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4578 Target Snapshot

Maternal embryonic leucine zipper kinase · SINGLE PROTEIN · Homo sapiens

2,667Compounds
380Assays
12Approved Drugs
1,953.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-12

Protein identity stays anchored to UniProt Q14680. Use UniProt Q14680 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q14680 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-12
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Maternal embryonic leucine zipper kinase as ChEMBL target CHEMBL4578, mapped to UniProt Q14680. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Maternal embryonic leucine zipper kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
ChEMBL target ID
CHEMBL4578
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
Q14680
Maternal embryonic leucine zipper kinase
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Maternal embryonic leucine zipper kinase is the right protein anchor across sources, using UniProt Q14680 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMaternal embryonic leucine zipper kinase
UniProt AccessionQ14680
Component TypeProtein
Sequence Length651 aa

Maternal embryonic leucine zipper kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Maternal embryonic leucine zipper kinase, mapped to UniProt Q14680. Sequence length is 651 aa.

Mapped IDQ14680
Review nameMaternal embryonic leucine zipper kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

12
Approved
8
Phase III
18
Phase II
18
Phase I
Assay Mix

Activity Type Distribution

IC50991.0
KI590.0
EC502.0
KD370.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4077934 9.82 IC50 0.15 Preclinical
CHEMBL3688335 9.52 IC50 0.3 Preclinical
CHEMBL3688376 9.52 IC50 0.3 Preclinical
CHEMBL3824328 9.52 IC50 0.3 Preclinical
CHEMBL1980995 9.5 Ki 0.3162 Preclinical
CHEMBL4062168 9.41 Ki 0.39 Preclinical
CHEMBL3688339 9.4 IC50 0.4 Preclinical
CHEMBL3692787 9.4 IC50 0.4 Preclinical
CHEMBL3692824 9.34 IC50 0.46 Preclinical
CHEMBL1908392 9.33 Ki 0.47 Preclinical
Distribution

pChEMBL Value Distribution

30
5.0
84
5.5
151
6.0
99
6.5
105
7.0
149
7.5
274
8.0
269
8.5
48
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

380
Total Assays
916
Tested Compounds
2
Assay Types
Binding — 378 assays, 916 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 308 830 7.9
assay format 42 33 6.7
cell-based format 23 22 7.3
subcellular format 5 31 5.9
Functional — 2 assays, 193 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 193 6.6
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine